Recent developments highlight IperionX's operational progress in titanium production capacity expansion, government contract awards, and market activity including analyst coverage and stock trading dynamics.

• IperionX targets a 200-ton titanium run rate as the U.S. supply chain takes shape, reflecting operational scale-up at its manufacturing campus [N1].
• The company received a prototype purchase order for U.S. Army heavy ground combat systems, indicating defense sector engagement [N11].
• BTIG initiated coverage of IperionX with a buy recommendation, and William Blair initiated coverage with an outperform recommendation, signaling analyst interest [N3][N12].
• Market commentary notes selling pressure on IPX stock, indicating investor caution or profit-taking [N2].

The company has demonstrated progress in scaling titanium powder production capacity to 200 metric tons per year and has secured significant U.S. government funding and contracts to support its manufacturing campus and the Titan Project. Its proprietary titanium processing technologies and integration of supply chain components position it to address domestic demand for titanium and critical minerals. Recent equity financing provides capital to support growth initiatives. Analyst coverage with buy and outperform recommendations reflects market interest. The company's ability to expand production capacity and advance the Titan Project could strengthen its position in the titanium supply chain.

IperionX continues to incur substantial net losses and negative operating cash flow as it invests heavily in R&D, production scale-up, and exploration without yet achieving significant revenue. The company depends on external financing, including equity raises and government funding, to sustain operations and fund expansion. Risks include potential delays or cost overruns in scaling production capacity, uncertainties in securing additional funding, and the possibility that government-owned assets may not be transferred to the company. Market selling pressure on the stock and the competitive landscape in critical materials add to execution risks.

IperionX's moat is based on its exclusive rights to patented titanium processing technologies developed from University of Utah research, which underpin its low-cost, low-carbon titanium metal production. The company's integration of titanium powder production and downstream manufacturing within a U.S.-based supply chain, supported by substantial U.S. government funding and contracts, provides strategic positioning in a critical materials market. The company's ongoing development of the Titan Project for domestic sourcing of titanium and critical minerals further enhances its potential competitive advantage. However, the moat is contingent on successful scale-up, commercialization, and securing additional funding to expand capacity and develop mineral resources.

• Funding and Capital Requirements: The company requires significant additional funding to expand production capacity and develop the Titan Project, which may involve equity dilution or debt financing. Failure to secure adequate financing could impede growth plans.
• Operational Scale-Up Risks: Scaling titanium powder production and downstream manufacturing involves technical and operational challenges. Delays or inefficiencies could impact production targets and financial performance.
• Dependence on Government Funding and Assets: Some assets used in production are acquired with U.S. government funds, with title vesting to the government during the funding agreement. The company may face risks if these assets are not transferred or if conditions are not met.
• Market and Competitive Risks: The company operates in a competitive environment for critical minerals and titanium supply. Market demand fluctuations and competitive pressures could affect commercial success.

• IperionX Ltd is a commercial producer of titanium metal products in the U.S., operating a Titanium Manufacturing Campus in Virginia and a Titanium Powder Facility (TPF).
• The company has transitioned to commercial titanium manufacturing operations, with titanium powder production commencing in 2024.
• By 2025, the company's titanium powder production nameplate capacity increased by 60% from 125 metric tons per year (tpa) to 200 tpa through operational and technology process improvements without additional capital expenditure.
• IperionX holds exclusive rights to commercialize patented titanium processing technologies originally discovered at the University of Utah.
• The company is advancing the Titan Project in Tennessee, which includes surface mining and mineral processing activities for titanium, rare earths, and zircon critical minerals.
• IperionX has received funding and contracts from the U.S. Department of the Army and Department of the Workforce (DoW) to support titanium production scale-up and the Titan Project development.
• The company incurred net losses of $66.8 million for fiscal 2026 and $35.3 million for fiscal 2025, reflecting ongoing investment in R&D, production scale-up, and exploration.
• Research and development expenses increased to $25.2 million in fiscal 2026, driven by increased staff costs, overheads, and commercialization activities including development of the GenX™ continuous HAMR™ platform.
• Exploration and evaluation expenses increased to $5.4 million in fiscal 2026, mainly due to technical and engineering work on the Titan Project.
• Corporate and administrative expenses rose to $25.9 million in fiscal 2026, reflecting increased personnel costs, ERP implementation, professional fees, and infrastructure to support growth and scale-up.
• Business development expenses were $4.0 million in fiscal 2026, consistent with prior year levels.
• Share-based payment expenses were $9.2 million in fiscal 2026, slightly decreased from prior year.
• Finance income decreased to $1.9 million in fiscal 2026 due to lower foreign exchange gains and interest income.
• Finance costs increased to $3.5 million in fiscal 2026, mainly from foreign exchange losses.
• Other income of $4.6 million in fiscal 2026 primarily relates to reimbursements from the U.S. DoW for expenditures on the Titan Project Definitive Feasibility Study (DFS) under the IBAS agreement.
• As of June 30, 2026, IperionX had cash reserves of $35.2 million and net assets of $88.3 million.
• The company completed a placement of 2,275,000 new fully paid ADSs in July 2026, raising approximately $50 million gross before costs.
• Capital expenditures were $19.0 million in fiscal 2026, mainly for property, plant, equipment, and exploration properties.
• Liquidity ratios as of December 31, 2025, include a current ratio of 4.03 and a cash ratio of 3.81, indicating strong short-term liquidity.
• The company has not yet achieved production volumes sufficient to generate significant revenue or positive operating cash flow and continues to incur losses during R&D, commissioning, and scale-up phases.
• IperionX's assets used in the TPF include equipment acquired with U.S. government funds, with title vesting with the government during the funding agreement term.
• The company retains optionality to expand TPF capacity to approximately 1,400 tpa, which would require additional funding potentially from debt, government, or equity sources.
• The Titan Project development requires substantial additional funding and may involve future debt, equity financing, or joint venture partnerships.
• Recent news highlights include targeting a 200-ton titanium run rate as the U.S. supply chain takes shape [N1], and receipt of a prototype purchase order for U.S. Army heavy ground combat systems [N11].
• Analyst coverage includes initiation by BTIG with a buy recommendation [N3] and William Blair with an outperform recommendation [N12].
• The company faces selling pressure in its stock as noted in recent market commentary [N2].